32.18
price down icon0.53%   -0.17
after-market アフターアワーズ: 32.18
loading
前日終値:
$32.35
開ける:
$32.57
24時間の取引高:
2.16M
Relative Volume:
1.91
時価総額:
$2.83B
収益:
$218.71M
当期純損益:
$-113.70M
株価収益率:
-24.69
EPS:
-1.3034
ネットキャッシュフロー:
$-73.47M
1週間 パフォーマンス:
+3.94%
1か月 パフォーマンス:
-2.75%
6か月 パフォーマンス:
+13.39%
1年 パフォーマンス:
+89.52%
1日の値動き範囲:
Value
$31.00
$32.84
1週間の範囲:
Value
$30.18
$38.10
52週間の値動き範囲:
Value
$15.84
$39.28

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Name
名前
Ideaya Biosciences Inc
Name
セクター
Healthcare (1112)
Name
電話
650-443-6209
Name
住所
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
職員
145
Name
Twitter
Name
次回の収益日
2026-02-13
Name
最新のSEC提出書
Name
IDYA's Discussions on Twitter

Compare IDYA vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IDYA icon
IDYA
Ideaya Biosciences Inc
32.18 2.84B 218.71M -113.70M -73.47M -1.3034
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
441.70 113.01B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
753.93 79.87B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
840.87 51.51B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
333.39 45.29B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
319.94 34.41B 5.36B 287.73M 924.18M 2.5229

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-07 再開されました UBS Buy
2025-11-24 開始されました Truist Buy
2025-09-18 開始されました Guggenheim Buy
2025-09-04 開始されました Barclays Overweight
2025-09-04 開始されました Citizens JMP Mkt Outperform
2025-07-22 開始されました TD Cowen Buy
2025-07-10 再開されました Goldman Neutral
2025-06-26 開始されました Wells Fargo Overweight
2024-11-18 開始されました Stephens Overweight
2024-11-05 ダウングレード Leerink Partners Outperform → Market Perform
2024-10-24 開始されました UBS Buy
2024-10-15 開始されました Cantor Fitzgerald Overweight
2024-07-08 開始されました Mizuho Outperform
2024-03-08 開始されました BTIG Research Buy
2023-08-08 開始されました SVB Securities Outperform
2023-05-24 開始されました Goldman Buy
2023-04-24 アップグレード Stifel Hold → Buy
2023-03-23 開始されました Berenberg Buy
2023-02-28 開始されました RBC Capital Mkts Outperform
2022-12-28 開始されました CapitalOne Overweight
2022-10-27 開始されました Citigroup Buy
2022-08-15 ダウングレード Stifel Buy → Hold
2022-07-18 再開されました Oppenheimer Outperform
2022-03-10 アップグレード Stifel Hold → Buy
2021-09-23 開始されました Stifel Hold
2021-06-04 再開されました Robert W. Baird Outperform
2021-03-11 開始されました Guggenheim Buy
2020-10-07 開始されました Wedbush Outperform
2020-09-01 開始されました Northland Capital Outperform
2020-07-13 アップグレード JP Morgan Neutral → Overweight
2020-06-17 繰り返されました H.C. Wainwright Buy
2020-04-06 開始されました H.C. Wainwright Buy
2020-03-13 開始されました ROTH Capital Buy
2019-10-17 開始されました Oppenheimer Outperform
2019-09-10 開始されました Robert W. Baird Outperform
2019-06-17 開始されました Citigroup Buy
2019-06-17 開始されました JP Morgan Neutral
2019-06-17 開始されました Jefferies Buy
すべてを表示

Ideaya Biosciences Inc (IDYA) 最新ニュース

pulisher
Apr 14, 2026

Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says - marketscreener.com

Apr 14, 2026
pulisher
Apr 14, 2026

Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals

Apr 14, 2026
pulisher
Apr 14, 2026

Guggenheim raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada

Apr 14, 2026
pulisher
Apr 14, 2026

RBC Capital raises Ideaya Biosciences stock price target on trial data - Investing.com Canada

Apr 14, 2026
pulisher
Apr 14, 2026

Novo teams with OpenAI; Ideaya gets muted response to eye drug data - Yahoo Finance

Apr 14, 2026
pulisher
Apr 14, 2026

IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma - Yahoo Finance

Apr 14, 2026
pulisher
Apr 13, 2026

IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal MelanomaSlideshow (NASDAQ:IDYA) 2026-04-13 - Seeking Alpha

Apr 13, 2026
pulisher
Apr 13, 2026

IDEAYA Biosciences, Inc. (IDYA) Latest Stock News & Headlines - Yahoo Finance

Apr 13, 2026
pulisher
Apr 13, 2026

Mizuho raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada

Apr 13, 2026
pulisher
Apr 13, 2026

Ideaya Biosciences: Stock Buoyant On Good mUM DataBut Approval Not A Formality (IDYA) - Seeking Alpha

Apr 13, 2026
pulisher
Apr 13, 2026

Truist raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada

Apr 13, 2026
pulisher
Apr 13, 2026

IDEAYA’s uveal melanoma drug combo meets trial goals By Investing.com - Investing.com Australia

Apr 13, 2026
pulisher
Apr 13, 2026

Goldman Sachs raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com South Africa

Apr 13, 2026
pulisher
Apr 13, 2026

Goldman Sachs raises Ideaya Biosciences stock price target on trial data - Investing.com Canada

Apr 13, 2026
pulisher
Apr 13, 2026

IDEAYA Biosciences (IDYA) Stock Jumps 26% After Eye Cancer Trial Blows Past Standard Care - MEXC

Apr 13, 2026
pulisher
Apr 13, 2026

IDEAYA Biosciences Announces Phase 2/3 Clinical Update for Darovasertib Combination in OptimUM-02 Trial - Minichart

Apr 13, 2026
pulisher
Apr 13, 2026

IDEAYA and Servier's eye cancer drug meets trial goal, paving way for FDA application - Reuters

Apr 13, 2026
pulisher
Apr 13, 2026

IDEAYA Biosciences (IDYA) Soars 26% on Breakthrough Eye Cancer Trial Data - MEXC

Apr 13, 2026
pulisher
Apr 13, 2026

Shares of This Cancer Therapy Maker Are Up 14%. Here’s Why. - Barron's

Apr 13, 2026
pulisher
Apr 13, 2026

IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock SoarsIDEAYA Biosciences (NASDAQ:IDYA) - Benzinga

Apr 13, 2026
pulisher
Apr 13, 2026

IDYA: Darovasertib plus crizotinib doubled PFS and improved ORR in HLA-A*02:01-negative mUM - TradingView — Track All Markets

Apr 13, 2026
pulisher
Apr 13, 2026

IDEAYA Biosciences stock surges 27% on trial results - Investing.com

Apr 13, 2026
pulisher
Apr 13, 2026

IDEAYA’s uveal melanoma drug combo meets trial goals - Investing.com

Apr 13, 2026
pulisher
Apr 13, 2026

IDEAYA Biosciences' darovasertib+crizotinib cuts progression risk 58%, median PFS 6.9 vs 3.1 months - TradingView — Track All Markets

Apr 13, 2026
pulisher
Apr 13, 2026

Darovasertib combo boosts PFS in IDEAYA (NASDAQ: IDYA) uveal melanoma trial - Stock Titan

Apr 13, 2026
pulisher
Apr 13, 2026

IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma - PR Newswire

Apr 13, 2026
pulisher
Apr 13, 2026

Why IDEAYA Biosciences Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga

Apr 13, 2026
pulisher
Apr 13, 2026

Dip Buying: Can IDEAYA Biosciences Inc reach all time highs this year2026 Momentum & Low Risk Growth Stock Ideas - baoquankhu1.vn

Apr 13, 2026
pulisher
Apr 13, 2026

Why Is Ideaya Biosciences (IDYA) Stock Surging Over 20% Overnight? - Stocktwits

Apr 13, 2026
pulisher
Apr 13, 2026

IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026 - BioSpace

Apr 13, 2026
pulisher
Apr 11, 2026

IDEAYA Biosciences to Announce Topline Results from Phase 2/3 Op - GuruFocus

Apr 11, 2026
pulisher
Apr 10, 2026

IDYA Stock Pops As New Cancer Trials Ignite Trader Focus - timothysykes.com

Apr 10, 2026
pulisher
Apr 10, 2026

Ideaya Biosciences to announce topline results from phase 2/3 Optimum-02 trial in metastatic uveal melanoma on Monday, April 13, 2026 - marketscreener.com

Apr 10, 2026
pulisher
Apr 10, 2026

Ideaya Biosciences To Announce Topline Results From Phase 2/3 Optimum-02 Trial In Metastatic Uveal Melanoma On Monday, April 13, 2026 - TradingView — Track All Markets

Apr 10, 2026
pulisher
Apr 10, 2026

IDEAYA to report uveal melanoma trial results Monday By Investing.com - Investing.com UK

Apr 10, 2026
pulisher
Apr 10, 2026

IDEAYA to reveal April 13 trial data in metastatic uveal melanoma - Stock Titan

Apr 10, 2026
pulisher
Apr 10, 2026

(IDYA) Volatility Zones as Tactical Triggers - Stock Traders Daily

Apr 10, 2026
pulisher
Apr 10, 2026

IDEAYA’s April 13 PFS Results May Lead to Fast-Track Approval or Significant Revaluation - Bitget

Apr 10, 2026
pulisher
Apr 09, 2026

Ideaya Biosciences announces clinical collaboration with AstraZeneca for lung cancer study - Investing.com

Apr 09, 2026
pulisher
Apr 09, 2026

IDEAYA, AstraZeneca launch global IDE849-Imfinzi lung cancer trial - TipRanks

Apr 09, 2026
pulisher
Apr 09, 2026

Ideaya Biosciences Incenters clinical collaboration agreement with AstraZeneca on April 8, 2026SEC filing - marketscreener.com

Apr 09, 2026
pulisher
Apr 09, 2026

IDEAYA Biosciences IncAdvancing Global Pha - Moomoo

Apr 09, 2026
pulisher
Apr 09, 2026

IDEAYA Biosciences (NASDAQ: IDYA) teams with AstraZeneca on IDE849-Imfinzi SCLC trial - Stock Titan

Apr 09, 2026
pulisher
Apr 08, 2026

Ideaya Biosciences: Key Pivotal Data Imminent - Seeking Alpha

Apr 08, 2026
pulisher
Apr 07, 2026

IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual Inhibitor - BioPharma APAC

Apr 07, 2026
pulisher
Apr 07, 2026

IDEAYA Biosciences, Inc. (IDYA) stock price, news, quote and history - Yahoo Finance UK

Apr 07, 2026
pulisher
Apr 07, 2026

Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), IDEAYA Biosciences (IDYA) and Bristol-Myers Squibb (BMY) - The Globe and Mail

Apr 07, 2026
pulisher
Apr 07, 2026

Jefferies Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $52 - Moomoo

Apr 07, 2026
pulisher
Apr 06, 2026

IDEAYA Biosciences Target of Unusually Large Options Trading (NASDAQ:IDYA) - MarketBeat

Apr 06, 2026
pulisher
Apr 06, 2026

Ideaya enrolls first patient in phase 1 trial of KAT6/7 inhibitor - Investing.com Canada

Apr 06, 2026
pulisher
Apr 06, 2026

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer - TradingView — Track All Markets

Apr 06, 2026

Ideaya Biosciences Inc (IDYA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$54.26
price up icon 2.69%
$48.70
price down icon 0.25%
$99.47
price up icon 1.08%
$152.54
price up icon 3.76%
$146.74
price down icon 4.34%
ONC ONC
$319.94
price up icon 3.21%
大文字化:     |  ボリューム (24 時間):